Thelansis

 Chordoma, an infrequent malignant tumor, can manifest in the spine and the base of the skull. This type of cancer originates from the notochord—a crucial embryonic mesodermal structure responsible for signaling tissue organization and differentiation—and accounts for 1 to 4% of all malignant bone tumors. In humans, the notochord eventually transforms into the nucleus pulposus. Chordomas predominantly occur in three locations: 50% in the sacrum, 35% in the skull base, and 15% in the vertebral bodies of the mobile spine (most commonly, the C2 vertebra, followed by the lumbar and thoracic spine). These tumors present as slow-growing, locally invasive growths, with rare occurrences of distant metastases, typically in the advanced stages of the disease. Despite their relatively benign nature, chordomas carry a significant risk of recurring locally. Chordomas are classified into four subtypes: conventional, poorly differentiated, dedifferentiated, and chondroid. Conventional (classic) c...

  A chordoma is a rare type of cancerous tumor that can occur anywhere along the spine, from the base of the skull to the tailbone. Chordomas grow slowly, gradually extending into the bone and soft tissue around them. Changes in the TBXT gene have been associated with chordoma. The TBXT gene provides instructions for making a protein called brachyury.  Worldwide, one in a million people are diagnosed with chordoma per year. Thelansis’s “Chordoma Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chordoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Chordoma across 8 MM market from the centre of Exc...